EGFR and non-small cell lung carcinoma: A large meta-analysis including 1,041 unselected NSCLC with BMs from 9 retrospective studies and 1 randomized controlled trial and aimed to investigate the combination of WBRT with EGFR TKI vs. WBRT alone or EGFR TKI therapy alone showed the best hazard ratios for intracranial PFS in patients who received EGFR-TKI alone [95].